SCHEMBL7205599

SCHEMBL7205599

CCOC(=O)CC1=COc2ccc(O)cc2O1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.43
CA12 O43570 4/20 0.40
CA1 P00915 4/20 0.40
CA2 P00918 4/20 0.40
CA7 P43166 4/20 0.40
CA9 Q16790 4/20 0.40
CA14 Q9ULX7 4/20 0.40
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
KMT2A Q03164 3/20 0.38
MIF P14174 1/20 0.38
ALDH1A1 P00352 5/20 0.37
HPGD P15428 3/20 0.37
GLA P06280 2/20 0.37
KDM4E B2RXH2 2/20 0.37
GAA P10253 2/20 0.37
CASP1 P29466 2/20 0.37
CASP7 P55210 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7204042 0.84 TSHR (0.43) CA12CA2CA7CA9CA14
SCHEMBL7199039 0.83 ALDH1A1 (0.40) CA12CA2CA9KMT2AALDH1A1
SCHEMBL9251348 0.79 CA12 (0.49) EGFRCA12CA1CA2CA7
SCHEMBL8580093 0.73 CA12 (0.49) EGFRCA12CA1CA2CA7
SCHEMBL27797500 0.70 EGFR (0.74) EGFRCA12CA1CA2CA7
SCHEMBL11965264 0.67 EGFR (0.58) EGFRCA12CA1CA2CA7
SCHEMBL8763431 0.67 EGFR (0.58) EGFRCA12CA1CA2CA7
SCHEMBL12345408 0.67 EGFR (0.55) EGFRCA12CA1CA2CA7
SCHEMBL31395505 0.67 EGFR (0.51) EGFRCA12CA1CA2CA7
SCHEMBL8113907 0.67 AKR1C2 (0.47) ALDH1A1HPGDKDM4EHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6602903-B2 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. LES LABORATORIES SERVIER (FR) 2003-08-05 US disclosed
US-20020052400-A1 Substituted heterocyclic compounds ADIR ET COMPAGNIE 2002-05-02 US disclosed
US-6313160-B1 FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052400-A1 Substituted heterocyclic compounds MTNR1A, MTNR1B, CBR1 EGFR 3034/4885CA12 1980/4885CA1 1773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.